Allogene (ALLO) insider to sell 4,167 shares in planned Rule 144 NASDAQ trade

Rhea-AI Filing Summary

Allogene Therapeutics insider plans Rule 144 stock sale. A holder has filed to sell 4,167 shares of Allogene Therapeutics common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $7,177.66. The shares were acquired on January 31, 2026 through restricted stock vesting under a registered compensation plan.

The planned sale is expected to occur around February 2, 2026 on the NASDAQ exchange. As of the notice, 224,730,144 shares of Allogene common stock were outstanding, providing context for the relative size of this planned transaction.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	4167	7177.66	224730144	02/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/31/2026	Restricted stock vesting under a registered plan	Issuer			4167	01/31/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Allogene (ALLO) Form 144 filing disclose?

The filing discloses a planned sale of 4,167 Allogene Therapeutics common shares under Rule 144. These shares, worth $7,177.66 in aggregate, are to be sold on NASDAQ, providing notice of an upcoming insider-related transaction in the company’s stock.

How many Allogene (ALLO) shares are being proposed for sale and at what value?

The notice covers a proposed sale of 4,167 common shares of Allogene Therapeutics. The aggregate market value listed is $7,177.66, giving investors a sense of the transaction’s dollar size relative to overall trading in the stock.

When were the Allogene (ALLO) shares to be sold under Form 144 acquired?

The 4,167 Allogene Therapeutics shares were acquired on January 31, 2026. They came from restricted stock vesting under a registered compensation plan, meaning the seller received them as part of compensation rather than via a cash market purchase.

When is the planned sale date for the Allogene (ALLO) Form 144 shares?

The filing lists an approximate sale date of February 2, 2026. This indicates when the holder expects to begin selling the 4,167 Allogene Therapeutics common shares on NASDAQ, subject to market conditions and Rule 144 requirements.

Through which broker will the Allogene (ALLO) Form 144 sale be executed?

The proposed transaction will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services in New York. This broker is named in the filing as the intermediary for selling the 4,167 Allogene Therapeutics common shares on the NASDAQ exchange.

How many Allogene (ALLO) shares are outstanding compared to the Form 144 amount?

The filing states that 224,730,144 Allogene Therapeutics common shares were outstanding. The proposed 4,167-share sale is small relative to this total, offering context for the scale of the planned insider-related transaction under Rule 144.